Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Project Team Eyes Coverage Discussions for Drug Use in Pre-Symptomatic Stage
May 20, 2025
- New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
May 20, 2025
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
May 16, 2025
- Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
May 16, 2025
- Biktarvy Gets Label Update to Add Eligible Patients
May 16, 2025
- Regional Formulary Push Pops Up from Ishin at 3-Party Talks
May 16, 2025
- Chuikyo OKs Listing of Tevimbra, Camzyos, Tremfya, and More
May 15, 2025
- Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
- Eylea’s Price to Be Axed by 19.5%, Jardiance 12.1% in Market Expansion Rule
May 15, 2025
- Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA
May 15, 2025
- Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
- Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme
May 15, 2025
- Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
- LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
- Health Minister Vows Cross-Ministry Response on Trump Executive Order
May 14, 2025
- MHLW Official Comments on PrEP Use of HIV Drugs: Diet
May 14, 2025
- LDP Project Team Proposes Review of Coverage Rules to Fuel Biosimilar Use
May 13, 2025
- Industry Renews Opposition to CEA Expansion at LDP Hearing
May 13, 2025
- MHLW Panel OKs Outline of Policy Directions to Spur Clinical Trials
May 13, 2025
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…